MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
|Podcasts|March 19, 2019
Ensuring Access to Generic Medications
Generic drugs offer treatment options that are as safe and effective as brand name drugs while also helping lower costs for both patients and health systems. It's estimated that over the last 10 years, generics have saved Americans $1.5 trillion
Advertisement
Generic drugs offer treatment options that are as safe and effective as brand name drugs while also helping lower costs for both patients and health systems. It's estimated that over the last 10 years, generics have saved Americans $1.5 trillion. However, there are still many off-patent medications that have few or no generic alternatives. And even when generics do exist, there are instances where the generic receives steep price increases or experiences shortages.
During this podcast, we speak with Ron Piervincenzi, PhD, chief executive officer (CEO) of the United States Pharmacopeia, and Martin Van Trieste, CEO of Civica Rx, about these issues and what their companies are doing to address them.
You may need to log in to the website to access this podcast.
Listen above or through one of these podcast services:
To read more on generics:
Advertisement
Related to this article
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
4
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
5